SlideShare a Scribd company logo
1 of 1
BILEACIDACTIVATEDRECEPTORS: TALE OF A MULTITASKING FAMILY
Nuclear receptors (NRs) are a largefamily of ligand-activated transcription factors
(Human NR superfamily include48 members) which controlnumerousmetabolic
pathways and processes in various organs, ranging from proliferation to apoptosis,
differentiation and energy homeostasis. Nuclear receptorsas valuable potential
targets for the development of therapeutic agents against a number of pathological
conditionsand diseases. Bile acids, arethe end-productsof cholestrolmetabolism
synthesized in the liver and secreted in the gastrointestinaltract where they
undergoesa transformation bythe intestinal microbiota. In addition to their role in
regulating lipid and cholesterol absorption in the small intestinal, bile acids area
signaling molecules acting on wide range of receptorscollectively known as Bile acid
activated receptors (BARs). This familyincludes NR such as The farnesoid X receptor
(FXR), theVitamin D receptor (VDR), thepregnane-x-receptor (PXR) among others
and G-protein coupled receptorssuch as GPBAR1 (TGR5). FXR isa bile sensor that
acts in coordination with other nuclear receptors to regulateessential steps in bile
acid uptake, metabolism and excretion. FXR shares the generalarchitecture of other
NR receptorsacting as an heterodimer with RXR (retinoid-x-receptor). In addition,
FXR is involved in lipid and glucose homeostasis. FXR ligands endowed with
agonistic activity areunder development for the treatment of metabolic disorders
linked to insulin resistance. GPBAR1 is a receptor regulating energy expenditureand
has relevance in the treatment of insulin resistance and diabetes along with
inflammation and immune dysfunction.
Objectives
- To describe cholesterol/bile acid metabolism and receptors
- Biology of BAR
- Medicinal chemistry of FXR and GPBAR1
-Potentialclinical application

More Related Content

Similar to Bile acid activated receptors

Nuclear receptors for developing new drug therapy By Dr. Armaan Singh
Nuclear receptors for developing new drug therapy By Dr. Armaan SinghNuclear receptors for developing new drug therapy By Dr. Armaan Singh
Nuclear receptors for developing new drug therapy By Dr. Armaan SinghDr. Armaan Singh
 
Nuclear receptors as target of new drug therapy
Nuclear receptors as target of new drug therapyNuclear receptors as target of new drug therapy
Nuclear receptors as target of new drug therapyHabibur Rahman
 
Peoxisomes in skin health&disease by prof m.y.abdel mawla
Peoxisomes  in skin health&disease  by  prof  m.y.abdel mawlaPeoxisomes  in skin health&disease  by  prof  m.y.abdel mawla
Peoxisomes in skin health&disease by prof m.y.abdel mawlaM.YOUSRY Abdel-Mawla
 
Transporter superfamilies in the human genome
Transporter superfamilies in the human genomeTransporter superfamilies in the human genome
Transporter superfamilies in the human genomeAkash Agnihotri
 
Guillian-Barre.Therapy.Experimental.
Guillian-Barre.Therapy.Experimental.Guillian-Barre.Therapy.Experimental.
Guillian-Barre.Therapy.Experimental.Dmitri Popov
 
The effect of pretreatment with Toll-like receptor 4 antagonist Resatorvid on...
The effect of pretreatment with Toll-like receptor 4 antagonist Resatorvid on...The effect of pretreatment with Toll-like receptor 4 antagonist Resatorvid on...
The effect of pretreatment with Toll-like receptor 4 antagonist Resatorvid on...Alaa Fadhel Hassan Alwazni
 
Final Report Anne Cox
Final Report Anne CoxFinal Report Anne Cox
Final Report Anne CoxAnne Cox
 
Peroxisomes in dermatology
Peroxisomes in dermatologyPeroxisomes in dermatology
Peroxisomes in dermatologygueste13bd2
 
Neural regulation
Neural regulationNeural regulation
Neural regulationabadoo
 

Similar to Bile acid activated receptors (20)

Nuclear receptors for developing new drug therapy By Dr. Armaan Singh
Nuclear receptors for developing new drug therapy By Dr. Armaan SinghNuclear receptors for developing new drug therapy By Dr. Armaan Singh
Nuclear receptors for developing new drug therapy By Dr. Armaan Singh
 
Nuclear receptors as target of new drug therapy
Nuclear receptors as target of new drug therapyNuclear receptors as target of new drug therapy
Nuclear receptors as target of new drug therapy
 
Ppar
PparPpar
Ppar
 
PPARs
PPARsPPARs
PPARs
 
Nuclear receptor
Nuclear receptorNuclear receptor
Nuclear receptor
 
Peroxisomes in dermatology
Peroxisomes in dermatologyPeroxisomes in dermatology
Peroxisomes in dermatology
 
Peroxisomes in dermatology.ppt
Peroxisomes in dermatology.pptPeroxisomes in dermatology.ppt
Peroxisomes in dermatology.ppt
 
Peoxisomes in skin health&disease by prof m.y.abdel mawla
Peoxisomes  in skin health&disease  by  prof  m.y.abdel mawlaPeoxisomes  in skin health&disease  by  prof  m.y.abdel mawla
Peoxisomes in skin health&disease by prof m.y.abdel mawla
 
Bile acids and NSAIDs and ASA
Bile acids and NSAIDs and ASABile acids and NSAIDs and ASA
Bile acids and NSAIDs and ASA
 
Final nuclear receptor
Final nuclear receptorFinal nuclear receptor
Final nuclear receptor
 
Peroxisomes in dermatology
Peroxisomes in dermatologyPeroxisomes in dermatology
Peroxisomes in dermatology
 
Transporter superfamilies in the human genome
Transporter superfamilies in the human genomeTransporter superfamilies in the human genome
Transporter superfamilies in the human genome
 
Guillian-Barre.Therapy.Experimental.
Guillian-Barre.Therapy.Experimental.Guillian-Barre.Therapy.Experimental.
Guillian-Barre.Therapy.Experimental.
 
Drug interactions linked to transporters
Drug interactions linked to transportersDrug interactions linked to transporters
Drug interactions linked to transporters
 
The effect of pretreatment with Toll-like receptor 4 antagonist Resatorvid on...
The effect of pretreatment with Toll-like receptor 4 antagonist Resatorvid on...The effect of pretreatment with Toll-like receptor 4 antagonist Resatorvid on...
The effect of pretreatment with Toll-like receptor 4 antagonist Resatorvid on...
 
Drug transporter polymorphism
Drug transporter polymorphismDrug transporter polymorphism
Drug transporter polymorphism
 
SURF Poster
SURF PosterSURF Poster
SURF Poster
 
Final Report Anne Cox
Final Report Anne CoxFinal Report Anne Cox
Final Report Anne Cox
 
Peroxisomes in dermatology
Peroxisomes in dermatologyPeroxisomes in dermatology
Peroxisomes in dermatology
 
Neural regulation
Neural regulationNeural regulation
Neural regulation
 

More from Attività scientifica

Il punto sul microbiota e le malattie umane- Covegno scientifico
Il  punto sul microbiota e le malattie umane- Covegno scientifico Il  punto sul microbiota e le malattie umane- Covegno scientifico
Il punto sul microbiota e le malattie umane- Covegno scientifico Attività scientifica
 
Portal hypertension and gastrointestinal bleeding
Portal hypertension  and gastrointestinal bleedingPortal hypertension  and gastrointestinal bleeding
Portal hypertension and gastrointestinal bleedingAttività scientifica
 
Ade 2018 emorragie Attività didattica integrativa 28 novembre 2017
Ade 2018 emorragie  Attività didattica integrativa  28 novembre 2017Ade 2018 emorragie  Attività didattica integrativa  28 novembre 2017
Ade 2018 emorragie Attività didattica integrativa 28 novembre 2017Attività scientifica
 
Ocaliva causes 114 serious side effects and 24 deaths according to FDA
Ocaliva  causes  114 serious side effects and 24 deaths according to FDAOcaliva  causes  114 serious side effects and 24 deaths according to FDA
Ocaliva causes 114 serious side effects and 24 deaths according to FDAAttività scientifica
 
Metabolomic profile of the probiotic of VSL#3 in vitro
Metabolomic profile of the probiotic of VSL#3 in  vitro   Metabolomic profile of the probiotic of VSL#3 in  vitro
Metabolomic profile of the probiotic of VSL#3 in vitro Attività scientifica
 
Nanomedecine - Just accepted for publication. Decoy receptor for CCR5
Nanomedecine - Just accepted for publication. Decoy receptor for CCR5Nanomedecine - Just accepted for publication. Decoy receptor for CCR5
Nanomedecine - Just accepted for publication. Decoy receptor for CCR5Attività scientifica
 
GPBAR1 (TGR5) regulates il 10 production from intestinal macrophages
GPBAR1 (TGR5) regulates il 10 production from intestinal macrophages  GPBAR1 (TGR5) regulates il 10 production from intestinal macrophages
GPBAR1 (TGR5) regulates il 10 production from intestinal macrophages Attività scientifica
 
Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1
Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1
Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1Attività scientifica
 
Digestive Disease Week 2017 The probiotic VSL#3 shows metabolic instability
Digestive Disease Week 2017 The probiotic VSL#3   shows metabolic instability Digestive Disease Week 2017 The probiotic VSL#3   shows metabolic instability
Digestive Disease Week 2017 The probiotic VSL#3 shows metabolic instability Attività scientifica
 
Digestive Disease Week 2017 BAR704 reduces liver fibrosis
Digestive  Disease  Week 2017    BAR704   reduces liver fibrosisDigestive  Disease  Week 2017    BAR704   reduces liver fibrosis
Digestive Disease Week 2017 BAR704 reduces liver fibrosisAttività scientifica
 
BAR501 a selective TGR5 ligand attenuates NASH
BAR501 a selective TGR5 ligand attenuates NASHBAR501 a selective TGR5 ligand attenuates NASH
BAR501 a selective TGR5 ligand attenuates NASHAttività scientifica
 

More from Attività scientifica (20)

Microbiota 2019
Microbiota  2019 Microbiota  2019
Microbiota 2019
 
Il punto sul microbiota e le malattie umane- Covegno scientifico
Il  punto sul microbiota e le malattie umane- Covegno scientifico Il  punto sul microbiota e le malattie umane- Covegno scientifico
Il punto sul microbiota e le malattie umane- Covegno scientifico
 
Microbiota update perugia-
Microbiota  update perugia- Microbiota  update perugia-
Microbiota update perugia-
 
Microbiota perugia 20 aprile 2018
Microbiota perugia 20 aprile 2018Microbiota perugia 20 aprile 2018
Microbiota perugia 20 aprile 2018
 
Portal hypertension and gastrointestinal bleeding
Portal hypertension  and gastrointestinal bleedingPortal hypertension  and gastrointestinal bleeding
Portal hypertension and gastrointestinal bleeding
 
Ade 2018 emorragie Attività didattica integrativa 28 novembre 2017
Ade 2018 emorragie  Attività didattica integrativa  28 novembre 2017Ade 2018 emorragie  Attività didattica integrativa  28 novembre 2017
Ade 2018 emorragie Attività didattica integrativa 28 novembre 2017
 
Ocaliva causes 114 serious side effects and 24 deaths according to FDA
Ocaliva  causes  114 serious side effects and 24 deaths according to FDAOcaliva  causes  114 serious side effects and 24 deaths according to FDA
Ocaliva causes 114 serious side effects and 24 deaths according to FDA
 
Metabolomic profile of the probiotic of VSL#3 in vitro
Metabolomic profile of the probiotic of VSL#3 in  vitro   Metabolomic profile of the probiotic of VSL#3 in  vitro
Metabolomic profile of the probiotic of VSL#3 in vitro
 
Nanomedecine - Just accepted for publication. Decoy receptor for CCR5
Nanomedecine - Just accepted for publication. Decoy receptor for CCR5Nanomedecine - Just accepted for publication. Decoy receptor for CCR5
Nanomedecine - Just accepted for publication. Decoy receptor for CCR5
 
GPBAR1 (TGR5) regulates il 10 production from intestinal macrophages
GPBAR1 (TGR5) regulates il 10 production from intestinal macrophages  GPBAR1 (TGR5) regulates il 10 production from intestinal macrophages
GPBAR1 (TGR5) regulates il 10 production from intestinal macrophages
 
Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1
Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1
Digestive Disease Week 2017 Discovery of dual LXR/GPBAR1
 
Digestive Disease Week 2017 The probiotic VSL#3 shows metabolic instability
Digestive Disease Week 2017 The probiotic VSL#3   shows metabolic instability Digestive Disease Week 2017 The probiotic VSL#3   shows metabolic instability
Digestive Disease Week 2017 The probiotic VSL#3 shows metabolic instability
 
Digestive Disease Week 2017 BAR704 reduces liver fibrosis
Digestive  Disease  Week 2017    BAR704   reduces liver fibrosisDigestive  Disease  Week 2017    BAR704   reduces liver fibrosis
Digestive Disease Week 2017 BAR704 reduces liver fibrosis
 
BAR501 a selective TGR5 ligand attenuates NASH
BAR501 a selective TGR5 ligand attenuates NASHBAR501 a selective TGR5 ligand attenuates NASH
BAR501 a selective TGR5 ligand attenuates NASH
 
NAFLD/NASH - 3 febbraio 2017-
NAFLD/NASH - 3  febbraio 2017-NAFLD/NASH - 3  febbraio 2017-
NAFLD/NASH - 3 febbraio 2017-
 
New official web site
New  official web siteNew  official web site
New official web site
 
Tgr5 and gastric cancer ddw2016
Tgr5 and gastric cancer  ddw2016Tgr5 and gastric cancer  ddw2016
Tgr5 and gastric cancer ddw2016
 
Bar501 and inflammation ddw 2016
Bar501 and inflammation ddw 2016Bar501 and inflammation ddw 2016
Bar501 and inflammation ddw 2016
 
Shp and liver fibrosis ddw 2016
Shp and liver fibrosis  ddw 2016Shp and liver fibrosis  ddw 2016
Shp and liver fibrosis ddw 2016
 
Ccr5 and colitis ddw 2016
Ccr5 and  colitis ddw 2016Ccr5 and  colitis ddw 2016
Ccr5 and colitis ddw 2016
 

Bile acid activated receptors

  • 1. BILEACIDACTIVATEDRECEPTORS: TALE OF A MULTITASKING FAMILY Nuclear receptors (NRs) are a largefamily of ligand-activated transcription factors (Human NR superfamily include48 members) which controlnumerousmetabolic pathways and processes in various organs, ranging from proliferation to apoptosis, differentiation and energy homeostasis. Nuclear receptorsas valuable potential targets for the development of therapeutic agents against a number of pathological conditionsand diseases. Bile acids, arethe end-productsof cholestrolmetabolism synthesized in the liver and secreted in the gastrointestinaltract where they undergoesa transformation bythe intestinal microbiota. In addition to their role in regulating lipid and cholesterol absorption in the small intestinal, bile acids area signaling molecules acting on wide range of receptorscollectively known as Bile acid activated receptors (BARs). This familyincludes NR such as The farnesoid X receptor (FXR), theVitamin D receptor (VDR), thepregnane-x-receptor (PXR) among others and G-protein coupled receptorssuch as GPBAR1 (TGR5). FXR isa bile sensor that acts in coordination with other nuclear receptors to regulateessential steps in bile acid uptake, metabolism and excretion. FXR shares the generalarchitecture of other NR receptorsacting as an heterodimer with RXR (retinoid-x-receptor). In addition, FXR is involved in lipid and glucose homeostasis. FXR ligands endowed with agonistic activity areunder development for the treatment of metabolic disorders linked to insulin resistance. GPBAR1 is a receptor regulating energy expenditureand has relevance in the treatment of insulin resistance and diabetes along with inflammation and immune dysfunction. Objectives - To describe cholesterol/bile acid metabolism and receptors - Biology of BAR - Medicinal chemistry of FXR and GPBAR1 -Potentialclinical application